ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer

Qin, Shukui*; Li, Jin; Bai, Yuxian; Wang, Zishu; Chen, Zhendong; Xu, Ruihua; Xu, Jianming; Zhang, Hongmei; Chen, Jia; Yuan, Ying; Liu, Tianshu; Yang, Lin; Zhong, Haijun; Chen, Donghui; Shen, Lin; Hao, Chunyi; Fu, Deliang; Cheng, Ying; Yang, Jianwei; Wang, Qiong; Qin, Baoli; Pan, Hongming; Zhang, Jun; Bai, Xianhong; Zheng, Qingshan复旦大学; 安徽医科大学; 上海交通大学; 哈尔滨医科大学; 浙江大学; 中国医学科学院; 中山大学; 中国科学院研究生院; 中国科学院; 中国医学科学院北京协和医院; 1; 5
Journal of Clinical Oncology2023-11-20DOI: 10.1200/JCO.22.02630
1被引4阅读
引用收藏
分享

摘要

K-Ras pancreatic cancers benefit overall survival in phase 3 NOTABLE study. @@@ PURPOSEIn a phase IIb trial of nimotuzumab plus gemcitabine, substantial clinical benefits were observed in patients with locally advanced or metastatic pancreatic cancer (PC). Therefore, we conducted a phase III clinical study to verify the efficacy and safety of this combination regimen in patients with K-Ras wild-type tumors (ClinicalTrials.gov identifier: NCT02395016).PATIENTS AND METHODSEligible patients were randomly assigned to receive nimotuzumab (400 mg once per week) or placebo followed by gemcitabine (1,000 mg/m2 on days 1, 8, and 15, once every 4 weeks) until disease progression or unacceptable toxicity. The primary end point was overall survival (OS) and the secondary end points were progression-free survival (PFS), response rates, and safety.RESULTSA total of 480 patients were screened; 92 patients were enrolled and 82 patients with K-Ras wild-type tumors were eligible. In the full analysis set, the median OS was 10.9 versus 8.5 months, while the restricted mean survival time (RMST) was 18.05 versus 11.14 months for the investigational versus control arm (ratio of control v investigation = 0.62 [0.40-0.97]; P = .036). Median PFS was 4.2 versus 3.6 months in the investigational versus control arm (log-rank P = .04; hazard ratio, 0.60 [0.37-0.99]) and the restricted mean PFS time was 8.08 versus 4.76 months (RMST ratio, 0.58 [0.38-0.90]; P = .036). Both OS and PFS were longer in the nimotuzumab group than in the placebo group. The objective response rates and disease control rates were 7% versus 10% and 68% versus 63% for the investigational and control groups, respectively. The incidence of adverse events were comparable between the two groups.CONCLUSIONIn patients with locally advanced or metastatic K-Ras wild-type PC, nimotuzumab plus gemcitabine significantly improved OS and PFS with a good safety profile.

学科与关键词

关键词
HAZARD RATIOSURVIVALCOMBINATIONMULTICENTERBENEFITTRIALS
相关
加载中…
  • Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.
    Qin, Shukui; Bai, Yuxian; Wang, Zishu; Chen, Zhendong; Xu, Ruihua; Xu, Jianming; Zhang, Hongmei; Chen, Jia; Yuan, Ying; Liu, Tianshu; Yang, Lin; Zhong, Haijun; Chen, Donghui; Shen, Lin; Hao, Chunyi; Fu, Deliang; Cheng, Ying; Yang, Jianwei; Bai, Xian Hong; Li, JinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 12
  • Nimotuzumab combined with concurrent chemo-radiotherapy in patients with locally advanced cervical squamous cell carcinoma: A randomized, controlled, open-label, multicenter study
    Wang, J.; Jiang, P.; Wei, L.; Zou, L.; Li, X.; Wang, C.; Sun, X.; Ding, L.; Yuan, X.; Cheng, H.; Wu, D.; Cai, R.; Yin, R.; Zhang, J.; Qiu, H.; Wang, T.; Gao, K.; Zhuo, Y.; Zhang, Y.; Zhao, F.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
  • Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.
    Sun, Yan; Hu, Chaosu; Lin, Qin; Gao, Li; Wang, Jianhua; Zhu, Xiaodong; Hao, Junfang; Lang, Jin Yi; Wang, Peiguo; Ye, Ming; Li, Xia; Xu, Benhua; Wu, Rong; Bai, Chunmei; You, Qingshan; Chen, Xiaozhong; Wang, Jun; Hu, Desheng; Wu, Gang; Pan, Jian-JiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Clinical Oncology
发表日期
2023-11-20
卷期
第 41 卷, 第 33 期
页码
5163-+
DOI
10.1200/JCO.22.02630
语言
ENGLISH
成果收录
SCIE
资助标注
Biotech Pharmaceutical Co, Ltd.

作者

  • Q

    Qin, Shukui (通讯) (第一作者)

    nanjing univ chinese med

  • L

    Li, Jin

查看全部 25 位作者收起作者
  • B

    Bai, Yuxian

    harbin med univ

  • W

    Wang, Zishu

    1 · bengbu med coll

  • C

    Chen, Zhendong

    2 · anhui med univ

  • X

    Xu, Ruihua

    sun yat sen univ

  • X

    Xu, Jianming

    5 · gen hosp peoples liberat army

  • Z

    Zhang, Hongmei

  • C

    Chen, Jia

  • Y

    Yuan, Ying

    2 · zhejiang univ

  • L

    Liu, Tianshu

    fudan univ

  • Y

    Yang, Lin

    chinese acad med sci · peking union med coll

  • Z

    Zhong, Haijun

    chinese acad sci · univ chinese acad sci · zhejiang canc hosp

  • C

    Chen, Donghui

    1 · shanghai jiao tong univ

  • S

    Shen, Lin

    peking univ canc hosp & inst

  • H

    Hao, Chunyi

    peking univ canc hosp & inst

  • F

    Fu, Deliang

    fudan univ

  • C

    Cheng, Ying

  • Y

    Yang, Jianwei

    fujian canc hosp · fujian med univ

  • W

    Wang, Qiong

  • Q

    Qin, Baoli

    liaoning canc hosp & inst

  • P

    Pan, Hongming

    zhejiang univ

  • Z

    Zhang, Jun

    ruijin hosp · shanghai jiao tong univ

  • B

    Bai, Xianhong

  • Z

    Zheng, Qingshan

    shanghai univ tradit chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417